KWS BioTest has a new CEO

KWS BioTest has a new CEO

10th December 2012 Bristol, UK, 10th December 2012 - Leading preclinical CRO, KWS BioTest, has today announced that Dr Robin Brown has been appointed as their new Chief Executive Officer.

Dr Brown brings a vast array of experience with him, acquired through working across the spectrum of drug discovery and development organizations including large pharma, biotechnology and venture capital healthcare investing. Dr Brown spent nine years at GSK, latterly as Head of Cell Biology; he was the Chief Scientific Officer of both Devgen and Galapagos (EBR:DEVG, EBR:GLPG), both of which are now publically listed companies and for the last eight years he has been a venture partner at Advent Healthcare Ventures responsible for a number of companies within the portfolio. He will take up the position of CEO at KWS BioTest in January.

His appointment will enable KWS to continue driving forwards with its expansion plans, positioning the company as the discovery partner of choice in the immunology/inflammation and infection disease areas.

Professor Neil Williams, Founder and CSO of KWS BioTest commented: "Over the past 8 years, we have built something really exciting in KWS, positioning the company to respond to the changing needs of drug discovery. Robin brings a wealth of experience in corporate development and drug discovery. His appointment is key to our ambitious growth plans for the company, and will enable us to reach our goal to be the premier science led CRO providing cell biology and pharmacology services for drug discovery".

Dr Robin Brown commented: "I have worked with KWS as a client and have come to understand the high quality of work the company is capable of delivering. The spiraling cost of drug discovery puts a premium on getting the best data as early as possible to assess the potential of new therapeutics. KWS is already well positioned to provide this and over the next few years intends to expand its capabilities to become one of the leading pre-clinical CRO's in Europe. It's an exciting time for the company and I look forward to helping them achieve their goals "


About KWS BioTest Ltd
KWS BioTest Ltd was established in 2004 as a CRO, bringing together internationally renowned scientific expertise in a commercially managed environment. KWS offers a wide range of preclinical services from primary and secondary screens through to complex disease models in the areas of infection, inflammation, autoimmunity, allergy, pain and metabolic disease. In all of these areas, KWS combines analysis of traditional disease parameters with bioanalytical and pathology services in order to work with customers to design and deliver bespoke programmes that meet their expectations.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.